Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Prediction Raises $4.5M

NEW YORK (GenomeWeb) – Genomic Prediction has raised $4.5 million through the sale of preferred stock in a financing round led by Nimble Ventures, the company said today. New investor PeopleFund also joined with Genomic Prediction's early investors.

The North Brunswick, New Jersey-based firm offers tests geared toward patients undergoing in vitro fertilization. It offers a next-generation sequencing-based test for chromosomal aneuploidies, gSeq, as well as an NGS-based test to screen for monogenic and polygenic diseases, EPgT. The gSeq test costs $150 per patient plus an additional $200 for each embryo that is screened, while EPgT costs $1,000, plus $400 per embryo.

The company plans to use the funding to expand its sales team and to further invest in data science. The firm received approval from the New Jersey Department of Health Clinical Laboratory Improvement Services to offer its two preimplantation genetic tests for monogenic disorders and polygenic disorders last September.

"Our cost-effective methodology of polygenic scoring builds on old technology from industrial agriculture, but we are the first in history to develop this technology to protect the human embryo," Genomic Prediction CEO Laurent Tellier said in a statement.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.